BTF granted US patent for 'Bioballs'
Thursday, 23 September, 2004
Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.
The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.
The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
